Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

As the EV Field Gets More Crowded, Hyliion May Start to Stand Out

By Chris Markoch, InvestorPlace Contributor

Hyliion's plug-and-play hybrid powertrain looked like a patchwork solution in our EV future. But with that future looking further away, HYLN stock may benefit.

Aphria Investors Are Just Waiting On the Votes to Be Counted

By Chris Markoch, InvestorPlace Contributor

Shares of APHA stock are falling prior to the shareholder's vote on the company's merger with Tilray. The difference in the spread makes Aphria a buy before the vote.

7 Bank Stocks to Watch as Q1 Earnings Kick Off

By Chris Markoch, InvestorPlace Contributor

April marks the beginning of earnings season, and banks have many reasons for optimism. Here are seven bank stocks that have potential upside.

This Is the Absolute Wrong Time to Consider Going Long on Microvision

By Chris Markoch, InvestorPlace Contributor

Shares of MVIS stock are up 180% this year. However, this pure play on LiDAR technology looks to have some short-term concerns. And maybe some long-term ones as well.

Tilray Bulls Should Chill and Root for Pullbacks Ahead Of Aphria Merger

By Chris Markoch, InvestorPlace Contributor

With its APHA merger nearly agreed upon, TLRY stock should look for, and actually cheer for, any pullbacks in the stock price.

What Can BioNTech Do for an Encore?

By Chris Markoch, InvestorPlace Contributor

If investors are expecting BNTX stock to continue generating double digit gains, they should be taking a careful look at its pipeline.

Pent-Up Post-Lockdown Demand, EV Fatigue May Keep Churchill Capital IV in Check

By Chris Markoch, InvestorPlace Contributor

Due to the intensified competition for discretionary dollars, CCIV stock could be kept in check for some time.

Are Investors Lowering the Bar for Pershing Square Tontine Holdings?

By Chris Markoch, InvestorPlace Contributor

PSTH stock is in a bearish pattern as investors begin to manage and perhaps lower their expectations for the company's target.

Buying Social Capital Hedosophia V Is a Big Swing at a Target That May Very Well Pay Off

By Chris Markoch, InvestorPlace Contributor

IPOE stock is one of the many SPACs being sponsored by Chamath Palihapitiya. Although his track record is mixed, Palihapitiya looks to have a winner with this one.

Naked Brands Either Makes No Sense or Makes Complete Sense

By Chris Markoch, InvestorPlace Contributor

NAKD stock is staying afloat as the company announces it has no debt and $270 million in cash. But does that capital make them the acquirer or the one being acquired?

Load More